HOME >> BIOLOGY >> NEWS
Jefferson Researchers Use Gene Therapy To Treat Rare, Inherited Brain Disease

Scientists Are Hoping The Treatment Provides Some Relief For A Young Girl, And Provides Insights To Future Uses Of Gene Therapy For Other Illnesses

Researchers at Jefferson Medical College are for the first time attempting to use gene therapy to treat Canavan disease, a rare, fatal metabolic brain disorder.

A team of neurosurgeons are treating a four-year-old Illinois girl at Thomas Jefferson University Hospital, Thomas Jefferson University, Philadelphia. The group includes Andrew Freese, M.D., Ph.D., associate professor of neurosurgery and director of neurosurgery research, Matthew During, M.D., professor of neurosurgery, Paola Leone, Ph.D., adjunct assistant professor of neurosurgery, and Giancarlo Barolat, M.D., professor of neurosurgery, as well as their colleagues there and at Yale University.

Canavan disease is an inherited neurological disorder characterized by spongy degeneration of the brain. It primarily affects children of Eastern European or Ashkenazi Jewish background. It is one of a group of genetic disorders called leukodystrophies that affect the growth of the myelin sheath of the nerve fibers in the brain. The myelin sheath is the fatty covering surrounding the nerve cells that acts as an insulator. The disease is caused by a genetic flaw in which an enzyme fails to be produced. The disease is incurable, resulting in the over-production of a toxic compound in the brain, N-acetyl-aspartate (NAA). Death usually occurs between the ages of 5 and 7.

Symptoms of Canavan disease, which appear in early infancy and progress quickly, may include mental retardation, loss of previously acquired motor skills, difficulty feeding, abnormal muscle tone, poor head control, and an abnormally enlarged head. As time progresses, sufferers also become paralyzed, blind, and lose hearing and their interaction with the outside world.

"Children fail to meet normal developmental milestones," Dr. Freese explain
'"/>

Contact: Steve Benowitz
steven.benowitz@mail.tju.edu
215-955-6300
Thomas Jefferson University
18-Mar-1998


Page: 1 2 3

Related biology news :

1. Jefferson Lab detector technology aids development of cystic fibrosis therapy
2. Jefferson scientists find gene expression pattern may predict behavior of leukemia
3. Jefferson researchers develop microchip to track genetic signature of cancer and normal tissue
4. Jefferson scientists use gene therapy to restore function of damaged heart cells in lab
5. Jefferson researchers uncover biochemical clues to how cells migrate in embryos
6. Jefferson and Brigham and Womens researchers find blue light important for setting biological clock
7. Jefferson Lab experiment generates THz radiation 20,000 times brighter than anyone else
8. Jefferson scientists show neural stem cells can become dopamine-making brain cells in laboratory
9. Jefferson scientists show how collagen gene mutation leads to osteoarthritis
10. Jefferson scientists use gene repair technique to change albino mice hairs to black
11. Jefferson scientists show drug is effective against a Hepatitis C Virus model in the laboratory

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/19/2020)... ... March 17, 2020 , ... Shoreline Biome , a ... strain level, recently unveiled a convenient new solution for the generation of 16S ... amplification capabilities as the Shoreline Complete kit. It is a convenient solution for ...
(Date:3/13/2020)... ... March 13, 2020 , ... ... of stored cord blood performed by Dr. Hal Boxmeyer and colleagues, which determined ... for cryogenically preserved cells under proper conditions. Cryo-Cell International marks the first family ...
(Date:3/13/2020)... ... March 13, 2020 , ... Acumed LLC ... be the exclusive distributor of the Louisville-based company’s orthobiologics portfolio. Under the terms ... to distribute Vivorte’s calcium phosphate-based bone allograft (Trabexus) and calcium phosphate-based biocement (Fortera). ...
Breaking Biology News(10 mins):
(Date:3/10/2020)... ... March 10, 2020 , ... Ortho Clinical Diagnostics, a ... laboratory solutions, announced its ORTHOTM Sera, ID-MTS, a suite of extended antigen in a ... cleared to run on ORTHO VISION® and ORTHO VISION® Max in the United States ...
(Date:3/3/2020)... Ill. (PRWEB) , ... March 03, 2020 , ... ... company serving the pharmaceutical, biotech and medical device industries, was recognized by INC. ... 5,000 puts forward annual lists to note industry leaders greatly impacting their spheres ...
(Date:2/21/2020)... ... February 20, 2020 , ... In a free ... speakers from Synteract including Lisa Dilworth, BS, MS, Vice President Rare, Orphan ... challenges, with feasible strategies and solutions to support patients, sites and sponsors. , When ...
(Date:2/19/2020)... ... February 18, 2020 , ... Shoreline Biome, ... to the strain level, recently unveiled a novel DNA isolation product. , Shoreline ... isolation of high molecular weight (HMW) single-stranded DNA (ssDNA) in excess of 40 ...
Breaking Biology Technology:
Cached News: